Core Insights - iAnthus Capital Holdings, Inc. is making significant progress in retail expansion, brand development, and capital structure initiatives in the cannabis industry [1] Retail Expansion - The Company plans to open its 26th GrowHealthy dispensary in Tequesta, Florida, on or about March 27, 2026, pending regulatory approvals, to enhance patient access in Palm Beach County [2] - The Tequesta dispensary aims to provide convenient access to high-quality cannabis products and is designed to meet the diverse wellness needs of the local community [3][4] Brand Development - In New Jersey, iAnthus has expanded its brand, The Vault, which features a curated archive of cannabis genetics aimed at resonating with distinct consumer segments [5] Capital Structure Initiatives - iAnthus, along with its subsidiary iAnthus New Jersey, LLC, has entered into amending agreements with related-party lenders to amend the terms of senior secured bridge notes issued on February 2, 2021 [6] - The maturity date of the Bridge Notes has been extended from February 16, 2026, to June 24, 2027, with an amendment fee of 2% of the principal amount, which is approximately US$8.4 million as of February 16, 2026 [7][8]

Core Viewpoint - FLSmidth & Co. A/S plans to initiate a new share buy-back programme of up to DKK 1.0 billion following the release of its Q1 2026 financial results, supported by a solid balance sheet and expected cash proceeds from the sale of its former corporate headquarters totaling DKK 730 million [1][2]. Group 1: Share Buy-Back Programme Details - The share buy-back programme aims to adjust FLSmidth's capital structure, with repurchased shares intended for cancellation at a General Meeting after the programme's completion [3]. - The programme is subject to approval at the Annual General Meeting on 24 March 2026, which includes renewing the Board of Directors' authorization to acquire own shares [4]. - The execution of the share buy-back will comply with EU regulations on market abuse and safe harbour provisions [5]. Group 2: Financial Timeline and Impact - The share buy-back programme is expected to commence after the Q1 2026 Interim Financial Report, anticipated on 13 May 2026, and is expected to be completed before the Annual General Meeting in 2027 [6]. - The new share buy-back initiative does not affect the ongoing programme, which is expected to conclude before the next Annual General Meeting on 24 March 2026 [7].

Core Viewpoint - Vivakor, Inc. has entered into forbearance agreements with eight investors to extend the maturity of its convertible promissory notes until January 2027, revising payment terms to support compliance with Nasdaq listing standards [1][2][4]. Group 1: Forbearance Agreements - The forbearance agreements allow noteholders to refrain from exercising default remedies, contingent on Vivakor's compliance with the amended terms [2]. - The agreements extend the maturity of the notes to January 2027 and establish revised payment schedules requiring scheduled cash payments through maturity [2]. Group 2: Company Strategy and Financial Position - Vivakor's CEO stated that these agreements provide additional time to address near-term obligations and align the capital structure while working to restore Nasdaq listing [3]. - The company is supported by a non-binding Letter of Intent to sell its midstream business and transportation assets for approximately $36 million, based on $4.56 million in annual EBITDA [3]. - The agreements reduce near-term maturity and conversion pressure while the company works to regain compliance with Nasdaq listing standards [3]. Group 3: Operational Context - Vivakor is an integrated provider of energy transportation, storage, reuse, and remediation services, operating one of the largest fleets of oilfield trucking services in the continental United States [6]. - The company aims to develop, acquire, and operate assets in the energy sector, providing services under long-term contracts [6].

Core Viewpoint - Bavarian Nordic A/S has announced a one-time share buy-back program of up to DKK 500 million to be executed over the next 12 months, reflecting a strong cash position and positive cash flow from operations [1][2]. Financial Position - As of September 30, 2025, Bavarian Nordic reported securities, cash, and cash equivalents totaling DKK 2,978 million, with approximately DKK 800 million earmarked for deferred payments to GSK and related royalties and taxes [2]. - The company believes that the cash balance after the buy-back program will be sufficient to maintain operational flexibility in an uncertain environment [2]. Share Buy-back Program Details - The shares bought back will be held as treasury stock to adjust the company's capital structure [3]. - The program will be executed in accordance with the authorization from the general meeting of shareholders and will comply with safe harbour regulations [3]. - Further details regarding the key terms of the program will be provided following the Board of Directors' final decision to launch the program [3]. Treasury Shares - Currently, Bavarian Nordic holds 966,845 shares as treasury shares, which represents 1.22% of the company's share capital [4]. - A portion of these treasury shares will be utilized to meet the company's obligations related to long-term share-based incentive programs for the Board of Directors and Executive Management [4]. Company Overview - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines, including mpox and smallpox vaccines, and has a strong portfolio of travel vaccines [5].